Reaction
Application Site Injury reporting signals
As of the last recalculation, Application Site Injury appears in 185 FAERS reports alongside 6 co-occurring drug terms. The strongest observed disproportionality signal is ALIROCUMAB (PRR 67.9).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Alirocumab | 14 | 67.9 | 67.9 |
| Alpelisib | 3 | 39.3 | 39.4 |
| Pegfilgrastim | 27 | 35.9 | 35.9 |
| Minoxidil Foam 5% (Womens) | 9 | 32.2 | 32.2 |
| Minoxidil | 9 | 23.6 | 23.6 |
| Tapentadol Hydrochloride | 6 | 20.8 | 20.8 |